The required amount of I-131 needed to achieve optimal outcomes of initial radioactive iodine therapy in differentiated thyroid cancer remains controversial. Further, clinical trials have sparked interest in the use of initial low-activity I-131 as treatment.
To learn more, researchers conducted a study comparing low-activity I-131 with high-activity I-131 in both low-risk and high-risk patients with differentiated thyroid cancer.
Their findings shed some light on which treatment may be most effective and most safe for patients.
READ FULL ARTICLE From press.endocrine.org